We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
INDP

Price
0.51
Stock movement up
+0.03 (6.25%)
Company name
Indaptus Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
6.13M
Ent value
982.88K
Price/Sales
3177.95
Price/Book
1.02
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-81.45%
3 year return
-48.30%
5 year return
-78.98%
10 year return
-
Last updated: 2025-04-15

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

INDP does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3177.95
Price to Book1.02
EV to Sales509.79

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count12.01M
EPS (TTM)-1.57
FCF per share (TTM)-1.21

Income statement

Loading...
Income statement data
Revenue (TTM)1.93K
Gross profit (TTM)873.00
Operating income (TTM)-15.37M
Net income (TTM)-14.89M
EPS (TTM)-1.57
EPS (1y forward)-1.38

Margins

Loading...
Margins data
Gross margin (TTM)45.28%
Operating margin (TTM)-214748.36%
Profit margin (TTM)-214748.36%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash7.38M
Net receivables0.00
Total current assets7.63M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets8.24M
Accounts payable555.95K
Short/Current long term debt107.99K
Total current liabilities2.23M
Total liabilities2.24M
Shareholder's equity6.00M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-11.53M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-11.53M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-248.09%
Return on Assets-180.75%
Return on Invested Capital-243.87%
Cash Return on Invested Capital-188.78%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.48
Daily high0.52
Daily low0.48
Daily Volume33K
All-time high61120.00
1y analyst estimate8.50
Beta1.13
EPS (TTM)-1.57
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
INDPS&P500
Current price drop from All-time high-100.00%-12.04%
Highest price drop-100.00%-56.47%
Date of highest drop14 Apr 20259 Mar 2009
Avg drop from high-69.54%-11.07%
Avg time to new high102 days12 days
Max time to new high1898 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
INDP (Indaptus Therapeutics Inc) company logo
Marketcap
6.13M
Marketcap category
Small-cap
Description
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Employees
7
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...